This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

ROBERT E. BURNS, M.D.

AMA Arch Derm. 1958;77(6):686-689.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

An effort is made herein to define the degree to which a dermatologist subjects his patients to the risk of fungous disease when he prescribes systemic steroid therapy.

A fair amount of animal experimentation has been performed with an eye to answering this question. Much of the information deals with Candida albicans, Coccidiodes immitis, and Histoplasma capsulatum, and a less amount deals with Cryptococcus neoformans and various actinomycetes. Strangely, I could find no relevant experimental work utilizing the aspergilli, which, clinically, have been major offenders.

Experimental Candida albicans infections in mice have usually been widely disseminated by the systemic administration of cortisone.^1-6 Scherr,² however, felt that in particularly severe Candida albicans infections cortisone actually had some ablative effect. He also believed that pituitary gonadotropic hormones lessened the tendency of the adrenocortical steroid to lower resistance to infection. Selye,⁷ on the other . . . [Full Text PDF of this Article]

Author Affiliations
Detroit

From the Department of Dermatology, Henry Ford Hospital (Clarence S. Livingood, Director).

Footnotes
Submitted for publication Jan. 28, 1958.

Presented as part of the Symposium on Diagnosis and Treatment of Fungous Infections (Edward P. Cawley, Director), American Academy of Dermatology and Syphilology, Chicago, Dec. 9, 1957.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?